These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

320 related items for PubMed ID: 21359879

  • 1. Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia.
    Pashos CL, Larholt K, Fraser KA, McKenzie RS, Senbetta M, Piech CT.
    Support Care Cancer; 2012 Jan; 20(1):159-65. PubMed ID: 21359879
    [Abstract] [Full Text] [Related]

  • 2. Propensity score matched assessment of treatment patterns and cost of erythropoiesis stimulating agent treatment in patients with cancer receiving myelosuppressive chemotherapy.
    Tunceli O, Bailey RA, Stephenson JJ, Singer J.
    J Oncol Pharm Pract; 2013 Dec; 19(4):305-14. PubMed ID: 23235918
    [Abstract] [Full Text] [Related]

  • 3. Drug utilisation and cost considerations of erythropoiesis stimulating agents in oncology patients receiving chemotherapy: observations from a large managed-care database.
    Vekeman F, McKenzie RS, Bookhart BK, Laliberté F, Duh MS, Tak Piech C, Lefebvre P.
    J Med Econ; 2009 Mar; 12(1):1-8. PubMed ID: 19450059
    [Abstract] [Full Text] [Related]

  • 4. The cost-effectiveness of weekly epoetin alfa relative to weekly darbepoetin alfa in patients with chemotherapy-induced anemia.
    Ben-Hamadi R, Duh MS, Aggarwal J, Henckler A, McKenzie RS, Tak Piech C.
    Curr Med Res Opin; 2005 Oct; 21(10):1677-82. PubMed ID: 16238908
    [Abstract] [Full Text] [Related]

  • 5. Dosing intervals and hemoglobin control in patients with chronic kidney disease and anemia treated with epoetin alfa or darbepoetin alfa: a retrospective cohort study.
    Nurko S, Spirko R, Law A, Dennis VW.
    Clin Ther; 2007 Sep; 29(9):2010-21. PubMed ID: 18035200
    [Abstract] [Full Text] [Related]

  • 6. Retrospective observational study of patients with chemotherapy-related anemia receiving erythropoietic agents.
    Mark TL, McKenzie RS, Fastenau J, Piech CT.
    Curr Med Res Opin; 2005 Sep; 21(9):1347-54. PubMed ID: 16197652
    [Abstract] [Full Text] [Related]

  • 7. Health economic evaluation of treating anemia in cancer patients receiving chemotherapy: a study in Belgian hospitals.
    Spaepen E, Demarteau N, Van Belle S, Annemans L.
    Oncologist; 2008 May; 13(5):596-607. PubMed ID: 18515745
    [Abstract] [Full Text] [Related]

  • 8. Utilization and cost comparison of erythropoiesis-stimulating agents in inpatient and outpatient hospital settings.
    Lafeuille MH, Bailey RA, Vekeman F, Scott McKenzie R, Lefebvre P.
    J Med Econ; 2012 May; 15(2):352-60. PubMed ID: 22168787
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Use of erythropoiesis-stimulating agents among chemotherapy patients with hemoglobin exceeding 12 grams per deciliter.
    Nordstrom BL, Luo W, Fraeman K, Whyte JL, Nordyke RJ.
    J Manag Care Pharm; 2008 May; 14(9):858-69. PubMed ID: 19006442
    [Abstract] [Full Text] [Related]

  • 11. Dosing patterns, hematologic outcomes, and costs of erythropoietic agents in predialysis chronic kidney disease patients with anemia.
    Papatheofanis FJ, McKenzie RS, Mody SH, Suruki RY, Piech CT.
    Curr Med Res Opin; 2006 May; 22(5):837-42. PubMed ID: 16709305
    [Abstract] [Full Text] [Related]

  • 12. Dosing patterns and costs of erythropoietic agents in patients with chronic kidney disease not on dialysis in managed care organizations.
    Duh MS, Mody SH, Scott McKenzie R, Lefebvre P, Gosselin A, Tak Piech C.
    Clin Ther; 2006 Sep; 28(9):1443-50. PubMed ID: 17062316
    [Abstract] [Full Text] [Related]

  • 13. Drug utilization and cost for erythropoiesis-stimulating agents in a long-term care resident population with chronic kidney disease.
    Lafeuille MH, Bailey RA, Vekeman F, Kilpatrick BS, Senbetta M, Piech CT, Lefebvre P.
    Consult Pharm; 2010 Aug; 25(8):493-500. PubMed ID: 20736158
    [Abstract] [Full Text] [Related]

  • 14. Dosing patterns and treatment costs of erythropoietic agents in elderly patients with pre-dialysis chronic kidney disease in managed care organisations.
    Duh MS, Mody SH, McKenzie RS, Lefebvre P, Gosselin A, Bookhart BK, Piech CT.
    Drugs Aging; 2006 Aug; 23(12):969-76. PubMed ID: 17154661
    [Abstract] [Full Text] [Related]

  • 15. Cost analysis of erythropoietic-stimulating therapy dosing in oncology inpatients.
    Killian AD, Gupta V, Goetz AE.
    Ann Pharmacother; 2006 Mar; 40(3):421-6. PubMed ID: 16507613
    [Abstract] [Full Text] [Related]

  • 16. Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dL versus > or = 10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trial.
    Vansteenkiste J, Hedenus M, Gascon P, Bokemeyer C, Ludwig H, Vermorken J, Hamilton L, Bridges K, Pujol B.
    BMC Cancer; 2009 Sep 03; 9():311. PubMed ID: 19728887
    [Abstract] [Full Text] [Related]

  • 17. Dosing patterns, drug costs, and hematologic outcome in anemic patients with chronic kidney disease switching from darbepoetin alfa to epoetin alfa.
    Hymes J, Bickimer T, Jackson JH, Bookhart BK, Mody SH, Tak Piech C.
    Curr Med Res Opin; 2007 Aug 03; 23(8):1931-7. PubMed ID: 17624232
    [Abstract] [Full Text] [Related]

  • 18. The importance of clinical variables in comparative analyses using propensity-score matching: the case of ESA costs for the treatment of chemotherapy-induced anaemia.
    Polsky D, Eremina D, Hess G, Hill J, Hulnick S, Roumm A, Whyte JL, Kallich J.
    Pharmacoeconomics; 2009 Aug 03; 27(9):755-65. PubMed ID: 19757869
    [Abstract] [Full Text] [Related]

  • 19. Cost analytic model to determine the least costly inpatient erythropoiesis stimulating therapy regimen.
    Sikand H, Decter A, Greco T, Watson SH, Kang YJ, Mody SH, Piech CT, Duh MS, Naeem A.
    Ann Pharmacother; 2008 Jan 03; 42(1):16-23. PubMed ID: 18029428
    [Abstract] [Full Text] [Related]

  • 20. Empirical methods to calculate an erythropoiesis-stimulating agent dose conversion ratio in nondialyzed patients with chronic kidney disease.
    Horowitz J, Agarwal A, Huang F, Gitlin M, Gandra SR, Cangialose CB.
    J Manag Care Pharm; 2009 Jan 03; 15(9):741-50. PubMed ID: 19954265
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.